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Abstract. The effect of doxorubicin and Congo Red on
prion protein (PrP) infectivity in experimental scrapie was
studied to better understand the effect of these compounds in
prion diseases and to establish whether a dose–response
correlation exists for Congo Red. This was performed in
order to test the effectiveness of compounds that may easily
be used in human prion diseases. Brain homogenate
containing membrane bound PrPSc monomers was used as
inoculum and was previously incubated with doxorubicin
10–3 M and with increasing concentrations of Congo Red
ranging from 10–7 to 10–2 M. This study shows for the first
time that doxorubicin, and confirms that Congo Red, may
interact with pathological PrP monomers modifying their
infectious properties. Pre-incubation of infected brain
homogenate with Congo Red resulted in prolonged
incubation time and survival, independently of Congo Red
concentration (p<0.05). Doxorubicin and Congo Red effects
do not depend upon interaction with PrP amyloid material.
Prion diseases (PD), also called transmissible spongiform
encephalopathies, are progressive and invariably fatal
neurodegenerative disorders of humans and animals. The most
common human form is Creutzfeldt-Jakob disease (CJD),
which accounts for almost 90%  of PD in humans. CJD, a
disease of middle-advanced age, is a dementing condition
associated with myoclonus and variable involvement of
cerebellar, pyramidal, extrapyramidal and brain stem structures.
Compared to the other neurodegenerative causes of dementia,
CJD has a relatively rapid course, usually leading to death
within a few months. Like other neurodegenerative disorders,
CJD may present in both sporadic and familial forms, both
clinically very similar. However, CJD is uniquely characterized
for its transmissibility to experimental animals by intracerebral
inoculation of infected brain tissue. This feature led to several
cases of iatrogenic CJD due to contamination of instruments
during neurosurgical procedures or administration of cadaveric-
derived pituitary hormones. The transmissibility of PD is
preserved in iatrogenic, sporadic and many familial forms.
Prions are self proteins (prion protein, or PrP) which during
PD undergo a conformational change which transforms them
into pathogenic proteins (1). In PD, the normal protease-
sensitive isoform (PrPC, or cellular PrP) is converted into the
pathological isoform (called PrPSc, from scrapie, the PD of
sheep) (2). PrPSc and PrPC share identical sequence and post-
translational modifications, but differ in their secondary
structure and biochemical properties. In particular, PrPSc has
a high content of beta-sheet, whereas PrPC contains 40%  of
alpha-helix structure (3-5).
Many drugs have been tested as potential therapeutic
agents for PD, but none of them has been demonstrated to
be effective in blocking or slowing the disease progression
if administered after the onset of clinical symptoms (6). At
present, no effective therapy is available but therapeutic
agents for transmissible spongiform encephalopathies are
emerging (7). Amphotericin B has been shown to delay
disease onset in experimental animals if treatment is started
around the inoculation date (8). MS-8209, a derivative of
amphotericin B with low toxicity, has proven effective both
in early and late treatments, but only when administered
before clinical onset (9). Quinacrine and chlorpromazine,
two drugs commonly used as therapeutic agents for different
human disorders, have been showed effective in reducing the
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production of PrPSc in vitro, but their effect in human PD
remains uncertain (10). Anti-PrP antibodies represent a
promising approach, even if therapy started after clinical
onset shows at present no effectiveness (11). Congo Red
belongs to a class of compounds characterized by the ability
to interact with amyloid. Congo Red can bind amyloid fibrils
made of pathological PrP and modifies their infectivity in
vitro and in vivo (12-14). Iododoxorubicin binds different
classes of amyloid fibrils, reduces amyloid deposition in
several types of amyloidosis and prolongs incubation time in
scrapie hamster (15, 16). A number of other compounds are
in the process of being evaluated for therapeutic use in PD:
phosphorothioate DNA, statins also associated with platelet-
activating factor, pentosan polysulfate, inhibitors of
dehydrocholesterol reductase and vaccination against PrP.
Some of these show promising partial effectiveness (17-20).
The aim of this work was to test the capacity of Congo
Red to interact with native membrane-bound PrPSc in the
inoculum and to reduce infectivity, and to test whether
Congo Red shows a dose-dependent effect. Also whether
doxorubicin, like iododoxorubicin, has an anti-prion effect
when added to native membrane-bound PrPSc in the
inoculum was tested.
Materials and Methods 
For the experimental plan, 44 Female Golden Syrian hamsters
(Charles River Italia, Lecco, Italy), weight 70-80 g (Table I) were
used. All animals were maintained in a controlled environment in
which light was on for 12 h per day (8:00-20:00 h). Hamsters were
housed in plastic boxes in groups of two. The animals were
inoculated intracerebrally with 30 μl of various inocula. For the
inoculation procedure, the animals were anesthetized by ether and
the solution injected by a insulin syringe in the right hemisphere.
The animals were observed daily and kept with free access to water
and food. The disease stage was evaluated upon clinical criteria:
stage 0 (healthy), stage 1 (hyper-reactivity), stage 2 (ataxia), stage
3 (complete paralysis, typical of the terminal stage of the disease).
All animals were sacrificed during stage 3 to prevent spontaneous
death with the consequent risk of tissue degradation. 
The inocula were prepared by using brain homogenates from
terminally ill Golden Syrian hamsters infected with the 263K
scrapie strain and diagnosed as affected by PD. The brain (approx.
1 g weight) was homogenized in cold PBS (10%  w/v) and
centrifuged at 3000 g for 10 minutes at 4˚C. The resulting pellet was
re-homogenized in the same volume and centrifuged under the same
conditions as in the first step. The supernatants obtained from both
centrifugation steps were then mixed, thus obtaining a 5%  brain
homogenate. The inocula were prepared by incubating for 60
minutes at RT a 1%  dilution of infected brain homogenate with
different concentrations of Congo Red (Sigma-Aldrich Italia, Milan,
Italy), ranging from 3×10–2 M to 3×10–7 M, or with doxorubicin
10–3 M (Table I). The rate of infectivity was evaluated according to
Prusiner et al. 
Means±SE of different inoculated groups were analyzed by the
analysis of variance (ANOVA) and Fisher’s test for multiple
comparisons. Cox’s regression analysis was used to assay the
presence of a relationship between incubation times, ataxia, survival
and the different Congo Red concentrations used in our experiments.
All statistical analyses were carried out with Graph Prism 3.0
statistical program (Prism Software Corporation, CA, USA). In all
analyses, the null hypothesis was rejected at the 0.05 level.
Results
One hamster died 48 hours after the inoculation, probably
because of the mechanical trauma due to intracerebral
inoculation. All remaining 43 hamsters developed classical
clinical signs of PD. The time interval from the inoculation
to the onset of the three different stages of the disease and
of death is reported.
As reported in Figure 1, the incubation period was longer in
the groups treated with Congo Red homogenates or
doxorubicin with respect the controls (p<0.005). In particular,
an increased incubation period was always observed between
treatments and controls. The highest difference resulted from
the comparison between controls vs. Congo Red 3×10–5
(p<0.001) and controls vs. doxorubicin 3×10–5 (p<0.001)
(Figure 1) since it was prolonged from a mean of 76 to 110
and 128 days, respectively. 
Ataxia duration during experimental scrapie was increased
by the preincubation with Congo Red and doxorubicin
(p<0.05). The animals infected with homogenate treated
with Congo Red 3×10–5 and doxorubicin 3×10–3 showed the
greatest delay (on average, 33 and 48 days compared to
controls, respectively) for the appearance of ataxia (p<0.001)
(Figure 2). 
In general, the time between inoculum and late disease
stage was significantly longer in treated animals than in
controls (p<0.05). Also in this case, the treatment with
Congo Red 3×10–5 and doxorubicin 3×10–3 showed the
maximum effectiveness (p<0.001) (Figure 3) since animal
survival shifted on average from 89 to 125 and 140 days,
respectively. 
The time between disease onset and death (disease
duration) was longer in all groups of treatment with respect to
controls (p<0.005) with no inter-group differences (Figure 4). 
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Table I. Experimental plan.
Group Number Inoculum Treatment
A 8 1%  Brain homogenate None
B 8 1%  Brain homogenate Congo Red 3×10–2
C 8 1%  Brain homogenate Congo Red 3×10–3
D 8 1%  Brain homogenate Congo Red 3×10–5
E 8 1%  Brain homogenate Congo Red 3×10–7
F 4 1%  Brain homogenate Doxorubicin 3×10–3
Total 44
Preincubation of brain homogenate with Congo Red
resulted in a marked decrease of infectivity titer. The
infectivity titer of the inocula were reduced 1,000 to 10,000
times in the five different preincubation treatments (Figure
5). The disease progression was also compared in the four
groups inoculated with different concentrations of Congo Red
to verify whether a dose–response relationship exists. Despite
variance analysis revealing a slight difference in incubation
times between the four groups (p<0.05), time intervals from
onset to the development of ataxia and of the terminal stage
resulted in no significant difference. Moreover, Cox
regression analysis excluded a dose–response relationship.
Discussion
Congo Red and other compounds, such as iododoxorubicin,
are able to bind amyloid fibrils and have good prospects for
systemic amyloidosis treatment (15, 22, 23). The experiments
that show the effectiveness of Congo Red and other
compounds in PD were carried out by adding these
compounds to a PrP27-30 preparation used as inoculum to
infect hamster or mouse except for the data reported by
Tagliavini et al. regarding iododoxorubicin (24). Thus Congo
Red and iodoxorubicin effectiveness in PD was attributed to
their interaction with PrP27-30 amyloid fibrils or to PrPSc
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Figure 1. Interval between inoculation and disease onset. *p<0.05,
**p<0.001.
Figure 2. Duration of ataxia in the treatment groups is shown. *p<0.05,
**p<0.001.
Figure 3. The time between inoculum and late stage of the disease
(phase 1 to 3) is reported. Duration was longer in all groups of
treatment than in controls. *p<0.05, **p<0.001.
Figure 4. The period between the onset of disease and death was longer
in all groups of treatment. *p<0.05.
aggregates (12, 13, 22, 25, 26). These compounds interact
directly with amyloid fibrils and PrPSc aggregates and might
disturb their geometry and recruitment of new molecules
(27). Iododoxorubicin has been shown to be able to bind to
amyloid, to hamper further aggregation and to induce amyloid
solubilization. Doxorubicin shows no similar effect.
Nowadays, most attempts to treat PD assume that PrPSc
production from PrPC is the crucial event (28) and that
PrPSc monomer inside the cell constitutes the key point for
disease induction (29).
This work provides additional evidence for the protective
action of Congo Red and doxorubicin in PD. These
experiments show that Congo Red and doxorubicin
significantly interact with PrPSc contained in the infected
brain homogenate of the inoculum.
There is evidence that in scrapie-infected cells Congo Red
inhibits the replication of the infectious agent and the
accumulation of the protease-resistant form of PrP (12). 
The mechanism of Congo Red interaction with membrane-
bound monomeric PrPSc is unknown but this interaction is able
to significantly reduce the infectivity titer of the inoculum, as
shown in these experiments. In fact, a pre-incubation of the
scrapie-infected brain homogenate with Congo Red and
doxorubicin in the present experimental conditions reduced
infectivity in the inoculum between 1,000 to 10,000 times with
respect to the pure homogenate. Moreover, a slowing down of
disease progression with increased disease duration has been
demonstrated in the animals injected with those inocula.
It should be stressed that brain homogenate from scrapie-
infected animals does not contain amyloid fibrils. In fact,
PrPSc tends to accumulate in neurons and to remain
membrane-bound. Thus, the effect of Congo Red and
doxorubicin must be attributed to their capacity to interact
with membrane-bound monomeric form of PrPSc. The
effectiveness of doxorubicin in decreasing infectivity in these
experimental conditions confirms that the mechanism
implicated is different from the capacity to bind amyloid
fibrils, because, unlike iododoxirubucin, doxorubicin does not
bind to amyloid. Congo Red and doxorubicin significantly
interact with PrPSc contained in infected brain homogenates,
thus modifying its molecular features and resulting in a
decrease of infectivity. The mechanism underlying the effect
of Congo Red is not known, but both overstabilization of
PrPSc and promotion of its clearance from the brain in the
injected animal, and interaction with PrPC preventing its
conversion to PrPSc have been hypothesized (12, 30, 31).
In order to evaluate whether the effectiveness of Congo Red
was dose-dependent, the inoculum was incubated with
increasing concentrations of Congo Red. The data show that
there is no dose/response correlation and that a major response
is reached also with low doses. In fact, the application of a Cox
regression model excluded a linear correlation between drug
increased concentration in the inoculum and the observed
effect. The dose/response curve may imply that the effect of
Congo Red reaches a plateau, beyond which a further increase
in its relative concentration produces no effective improvement.
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Figure 5. Infectivity Titer. The infectivity titer is calculated by Prusiner’s equation and is reduced in all groups infected whit homogenate treated with
Congo Red (CR) and in the group treated with Doxorubicin (Doxo).
Congo Red has also shown an in vivo anti-scrapie effect in
hamster (31). In fact, hamsters infected with scrapie agent
were treated with intraperitoneal injection of Congo Red
before, during and after inoculum and the incubation period
was evaluated (31). The data showed that an in vivo treatment
with Congo Red immediately after inoculum can prolong the
incubation period, but cannot slow disease progression.
Unfortunately the data show that this compound is effective
only when it is administered at the time of infection. 
The presented experiments show that Congo Red and
doxorubicin produce their effect when added to the
inoculum, in the absence of significant amounts of amyloid,
through an interaction with monomeric membrane-bound
PrPSc. These data are experimental evidence that some
compounds can interfere with the interaction of PrPC and
PrPSc. This interaction is responsible for the conversion of
PrPC to its protease-resistant form which is the basis of
prion disease pathogenesis. These data suggest that Congo
Red and doxorubicin may be used in the treatment of PD,
but Congo Red effectiveness is limited and cannot be further
increased by dose augmentation. Despite doxorubicin never
having been tested as anti-prion drug in an in vivo
experiment, it is commonly used for treating different types
of cancer and its safety profile is well known. Thus, the
evaluation of the anti-prion effect of doxorubicin when
administered after disease onset might be an interesting
perspective of this study. Different compounds with different
action-mechanisms may be combined to increase overall
effectiveness in the treatment of PD.
Acknowledgements
This work was supported by the Italian Ministry of Health, Grant
for Finalized Research (RF01; MS, N° 128, 10/2001).
References
1 Prusiner SB: Molecular biology of prion diseases. Science 252:
1515-1522, 1991. 
2 Prusiner SB, Scott MR, DeArmond SJ and Cohen FE: Prion
protein biology. Cell 93: 337-348, 1998. 
3 Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF and
Caughey WS: Secondary structure analysis of the scrapie-
associated protein PrP 27-30 in water by infrared spectroscopy.
Biochemistry 30: 7672-7680, 1991. 
4 Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D,
Mehlhorn I, Huang Z, Fletterick RJ, Cohenu FE and Prusiner
SB: Conversion of alpha-helices into beta-sheets features in the
formation of the scrapie prion proteins. Proc Natl Acad Sci USA
90: 10962-10966, 1993. 
5 Safar J, Roller PP, Gajdusek DC and Gibbs CJ Jr: Conformational
transitions, dissociation, and unfolding of scrapie amyloid (prion)
protein. J Biol Chem 268: 20276-20284, 1993. 
6 Dormont D: Approaches to prophylaxis and therapy. Br Med
Bull 66: 281-292, 2003. 
7 Koster T, Singh K, Zimmermann M and Gruys E: Emerging
therapeutic agents for transmissible spongiform encephalopathies:
a review. J Vet Pharmacol Ther 26: 315-326, 2003. 
8 Adjou KT, Privat N, Demart S, Deslys JP, Seman M, Hauw JJ
and Dormont D: MS-8209, an amphotericin B analogue, delays
the appearance of spongiosis, astrogliosis and PrPres
accumulation in the brain of scrapie-infected hamsters. J Comp
Pathol 122: 3-8, 2000.
9 Beringue V, Adjou KT, Lamoury F, Maignien T, Deslys JP, Race
R and Dormont D: Opposite effects of dextran sulfate 500, the
polyene antibiotic MS-8209, and Congo red on accumulation of
the protease-resistant isoform of PrP in the spleens of mice
inoculated intraperitoneally with the scrapie agent. J Virol 74:
5432-5440, 2000. 
10 Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo
L, De Luigi A, Limido L, Suardi S, Rossi G, Auvré F, Adjou KT,
Salès N, Williams A, Lasmézas C and Deslys JP: Evaluation of
quinacrine treatment for prion diseases. J Virol 77: 8462-8469,
2003. 
11 Korth C and Peters PJ: Emerging pharmacotherapies for
Creutzfeldt-Jakob disease. Arch Neurol 63: 497-501, 2006.
12 Caughey B, Ernst D and Race RE: Congo red inhibition of
scrapie agent replication. J Virol 67: 6270-6272, 1993. 
13 Caughey B, Brown K, Raymond GJ, Katzenstein GE and
Thresher W: Binding of the protease-sensitive form of PrP (prion
protein) to sulfated glycosaminoglycan and congo red corrected.
J Virol 68: 2135-2141, 1994. 
14 Rudyk H, Vasiljevic S, Hennion RM, Birkett CR, Hope J and
Gilbert IH: Screening Congo Red and its analogues for their
ability to prevent the formation of PrP-res in scrapie-infected
cells. J Gen Virol 81: 1155-1164, 2000. 
15 Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E,
Perfetti V, Ferrari M, Zorzoli I, Marinone MG, Garini P,
Diegoli M, Trizio D, and Ballarini D: Interaction of the
anthracycline 4’-iodo-4’-deoxydoxorubicin with amyloid
fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA
92: 2959-2963, 1995. 
16 Palha JA, Ballinari D, Amboldi N, Cardoso I, Fernandes R, Bellotti
V, Merlini G and Saraiva MJ: 4’-Iodo-4’-deoxydoxorubicin
disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol
156: 1919-1925, 2000. 
17 Ludewigs H, Zuber C, Vana K, Nikles D, Zerr I and Weiss S:
Therapeutic approaches for prion disorders. Expert Rev Anti
Infect Ther 5: 613-630, 2007. 
18 Vana K, Zuber C, Nikles D and Weiss S: Novel aspects of
prions, their receptor molecules, and innovative approaches for
TSE therapy. Cell Mol Neurobiol 27: 107-128, 2007. 
19 Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A and Doh-
Ura K: Experimental treatments for human transmissible
spongiform encephalopathies: is there a role for pentosan
polysulfate? Expert Opin Biol Ther 7: 713-726, 2007. 
20 Bade S and Frey A: Potential of active and passive immunizations
for the prevention and therapy of transmissible spongiform
encephalopathies. Expert Rev Vaccines 6: 153-168, 2007. 
21 Prusiner SB, Cochran SP, Groth DF, Downey DE, Bowman KA
and Martinez HM: Measurement of the scrapie agent using an
incubation time interval assay. Ann Neurol 11: 353-8, 1982.
22 Caughey B and Race RE: Potent inhibition of scrapie-associated
PrP accumulation by Congo Red. J Neurochem 59: 768-771,
1992. 
Corato et al: Doxorubicin and Congo Red Reduce Prion Infectivity
2511
23 Poli G, Martino PA, Villa S, Carcassola G, Giannino ML,
Dall’Ara P, Pollera C, Iussich S, Tranquillo VM, Bareggi S,
Mantegazza P and Ponti W: Evaluation of anti-prion activity of
Congo Red and its derivatives in experimentally infected
hamsters. Arzneimittelforschung 54: 406-415, 2004. 
24 Tagliavini F, McArthur RA, Canciani B, Giaccone G, Porro M,
Bugiani M, Lievens PM, Bugiani O, Peri E, Dall’Ara P, Rocchi
M, Poli G, Forloni G, Bandiera T, Varasi M, Suarato A, Cassutti
P, Cervini MA, Lansen J, Salmona M and Post C: Effectiveness
of anthracycline against experimental prion disease in Syrian
hamsters. Science 276: 1119-1122, 1997. 
25 Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A and
Gabizon R: The anti-prion activity of Congo Red. Putative
mechanism. J Biol Chem 273: 3484-3489, 1998. 
26 Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani
B, Angeretti N, Giampaolo L, Peressini E, Awan T, De Gioia L,
Ragg E, Bugiani O and Salmona M: Tetracycline affects
abnormal properties of synthetic PrP peptides and PrP(Sc) in
vitro. J Mol Biol 300: 1309-1322, 2000. 
27 Aguzzi A, Glatzel M, Montrasio F, Prinz M and Heppner FL:
Interventional strategies against prion diseases. Nat Rev
Neurosci 2: 745-749, 2001. 
28 Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A,
Kobayashi Y, Marino S, Weissmann C and Aguzzi A: Normal
host prion protein necessary for scrapie-induced neurotoxicity.
Nature 379: 339-343, 1996. 
29 Brandner S, Raeber A, Sailer A, Blättler T, Fischer M,
Weissmann C and Aguzzi A: Normal host prion protein (PrPC)
is required for scrapie spread within the central nervous system.
Proc Natl Acad Sci USA 93: 13148-13151, 1996. 
30 Ladogana A, Casaccia P, Ingrosso L, Cibati M, Salvatore M, Xi
YG, Masullo C and Pocchiari M: Sulphate polyanions prolong
the incubation period of scrapie-infected hamsters. J Gen Virol
73(Pt 3): 661-665, 1992. 
31 Ingrosso L, Ladogana A and Pocchiari M: Congo Red prolongs
the incubation period in scrapie-infected hamsters. J Virol 69:
506-508, 1995. 
Received December 3, 2008
Revised February 24, 2009
Accepted March 30, 2009
ANTICANCER RESEARCH 29: 2507-2512 (2009)
2512
